Personalis, Inc. (PSNL) Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; NeXT Personal, a specific liquid biopsy designed for individual patient tumor tracking; the NeXT Dx Test, a genomic cancer profiling tool that identifies composite biomarkers for treatment guidance; and the sophisticated NeXT SHERPA and NeXT NEOPS for predicting neoantigens. Additionally, Personalis offers the ACE platform, utilized for diverse clinical and therapeutic applications like neoantigen prediction, biomarker identification, and the selection of new drug targets. Their clientele includes biopharmaceutical companies, academic institutions, non-profit organizations, and government entities. The company has established significant partnerships with organizations such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center. Personalis, Inc. was founded in 2011 and is based in Menlo Park, California.
Sector: Services-Medical Laboratories
Industry: Medical - Diagnostics & Research
Personalis, Inc. NASDAQ:PSNL Healthcare · Medical - Diagnostics & Research
Mkt Cap $1.69B
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Are PAG, BRBS, PSNL Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC, an investor rights law firm, announced it is investigating Blue Ridge Bankshares' sale to HomeTrust Bancshares for potential breaches of fiduciary duty to shareholders.
Under the deal, Blue Ridge shareholders would receive 0.086 HomeTrust shares per share and own roughly 35% of the combined company.
The release is a routine law-firm solicitation seeking shareholder clients on a contingent-fee basis, not an issuer disclosure or court action; no claims have been filed.
• 2d ago AI analysis › Press Release
Are BWMN, PAG, CCC, PSNL Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC, a plaintiff investor-rights law firm, announced investigations of pending acquisitions of BWMN, PAG, CCC, and PSNL for potential fiduciary-duty breaches.
For BWMN, the release cites the proposed $43.00-per-share cash sale to Bernhard Capital Partners and claims insiders may receive benefits unavailable to ordinary shareholders.
The release is law-firm solicitation with no new issuer disclosure and may seek increased consideration or additional disclosures; treat as low-signal noise.
• 5d ago AI analysis › Press Release ⚠ 1
PSNL Investor Investigation: Personalis Shareholders Are Alerted to the Pending Investigation into the $16.25 per Share Merger
Bleichmar Fonti & Auld LLP announced it is investigating the take-private merger of Personalis by Tempus AI at an anchored price of $16.25 per share.
The firm is probing whether Tempus' prior 12.5% stake and commercial relationship with Personalis created breaches of fiduciary duty under Delaware law and whether the per-share price is fair to public holders.
The release is a plaintiff-firm solicitation seeking stockholder contact on a contingency basis; it contains no new disclosure from Personalis itself.
• 5d ago AI analysis › Press Release
Are VRNS, DSGR, PSNL Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC, an investor rights law firm, announced it is investigating Distribution Solutions Group's $35.00-per-share cash sale to affiliates of LKCM Headwater Investments for potential fiduciary-duty breaches.
The same release also targets Varonis Systems' $49.75-per-share sale to Proofpoint and Personalis' $16.25-per-share sale to Tempus AI.
This is law-firm solicitation, not an issuer disclosure; no court action or settlement is announced and the DSGR deal terms themselves are unchanged.
• 10d ago AI analysis › Press Release
Personalis NeXT Personal® Data Showcasing Ultrasensitive MRD to be Presented at ESMO 2026
Personalis will present four NeXT Personal ctDNA datasets at the ESMO Congress 2026, October 23-27 in Madrid, including two oral presentations.
The late-breaking oral covers updated overall survival and ctDNA outcomes from the C-POST Phase 3 trial of adjuvant cemiplimab in high-risk cutaneous squamous cell carcinoma, and a Rapid Oral will show first pre-interim data from the prospective B-STRONGER-1 study of ultrasensitive MRD detection in early-stage triple-negative breast cancer.
The presentations expand the clinical evidence base for NeXT Personal across solid tumors, though no new efficacy figures are disclosed ahead of the meeting.
• 11d ago AI analysis › Press Release
Personalis Brings Resistance Mutation Tracking to NeXT Personal® MRD Test
Personalis commercially launched Real-Time Variant Tracker, optional supplemental results within its NeXT Personal MRD test that track resistance and therapeutically targetable variants as cancer biology evolves.
The feature identifies clinically significant variants tied to FDA-approved therapies and NCCN guidelines, and moved from an Early Access Program begun in January 2026 to full commercial availability on October 20, 2026.
The launch deepens the NeXT Personal product offering and could support pricing and physician adoption, though no revenue contribution was quantified.
• 12d ago AI analysis › Press Release ⚠ 2
Are MKTX, HOWL, PSNL Obtaining Fair Deals for their Shareholders?
Plaintiff law firm Halper Sadeh LLC announced it is investigating Werewolf Therapeutics (HOWL) for potential violations of federal securities laws and breaches of fiduciary duties relating to its proposed merger with Ambros Therapeutics.
Under the proposed transaction, Werewolf shareholders are expected to own approximately 6.8% of the combined company upon closing.
The same release also probes MarketAxess's $167.00-per-share sale to Intercontinental Exchange and Personalis's $16.25-per-share sale to Tempus AI. This is a routine law-firm investor solicitation wired under the firm's own name, not a disclosure from any of the issuers.
• 1mo ago AI analysis › Press Release ⚠ 1
Are PSNL, MKTX, BZH, HOWL Obtaining Fair Deals for their Shareholders?
Plaintiff law firm Halper Sadeh LLC announced it is investigating Beazer Homes USA's pending $33.50-per-share cash sale to Dream Finders Homes for potential violations of securities laws and breaches of fiduciary duties to shareholders.
The release is a shareholder solicitation, not a company disclosure: it asks Beazer holders to contact the firm about their rights on a contingency basis and says it may seek increased consideration, additional disclosures, or other relief. It also warns deal terms may limit superior competing offers.
The same notice covers three other pending deals: Personalis' sale to Tempus AI at $16.25 per share, MarketAxess' $167.00-per-share cash sale to Intercontinental Exchange, and Werewolf Therapeutics' merger with Ambros Therapeutics, under which Werewolf shareholders would own approximately 6.8% of the combined company.
Treat this as low-signal law-firm marketing; no new disclosure from Beazer itself and no certified class or settlement announced.
• 1mo ago AI analysis › Press Release ● Major ⚠ 4
Personalis Reports Second Quarter Results and Recent Highlights
Personalis reported Q2 revenue of $22.4 million, up 30% year-over-year, driven primarily by a 442% surge in clinical revenue to $2.6 million.
Clinical test volume jumped 199% YoY to 10,384 tests, bolstered by new Medicare coverage approvals for NeXT Personal in immunotherapy monitoring and neoadjuvant breast cancer monitoring.
Following the July 20 announcement of a merger with Tempus AI, the company suspended full-year financial guidance and will not hold an earnings call.
• 2mo ago AI analysis › Press Release
Are BOW, UTZ, PSNL Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC is investigating Bowhead Specialty Holdings regarding its proposed sale to American Family Mutual Insurance Company for $34.00 per share in cash.
The law firm is examining whether the transaction involves potential violations of federal securities laws or breaches of fiduciary duties to shareholders.
This release is a solicitation encouraging shareholders to contact the firm to discuss their rights and options on a contingent fee basis.
• 2mo ago AI analysis › Press Release
Are FNWD, PSNL, DSGR Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC is investigating the proposed sale of Distribution Solutions Group to affiliates of LKCM Headwater Investments for $35.00 per share in cash.
The firm is examining potential violations of federal securities laws or breaches of fiduciary duties related to the transaction terms.
Shareholders are encouraged to contact the firm to discuss their rights and options regarding the deal.
• 3mo ago AI analysis › Press Release
Are PSNL, LXP, DSGR, ATAI Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC is investigating AtaiBeckley Inc. regarding the proposed sale to Eli Lilly and Company for $6.75 per share in cash plus a Contingent Value Right.
The law firm is examining whether the proposed transaction contains terms that limit superior offers or fail to provide fair value to shareholders.
Shareholders are encouraged to contact the firm to discuss rights, though this release is a standard solicitation rather than an issuer disclosure.
• 3mo ago AI analysis › Press Release ● Critical ⚠ 2
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
Personalis agreed to be acquired by Tempus AI for $16.25 per share in a stock transaction, implying a total enterprise value of $1.5 billion.
The offer represents a 28% premium to the unaffected 30-day VWAP, building on the companies' existing partnership to integrate Personalis' MRD technology with Tempus' AI platform.
The transaction is expected to close in late 2026 or early 2027, subject to shareholder and regulatory approvals, with Tempus retaining the option to pay up to 50% of the consideration in cash.
• 3mo ago AI analysis › Press Release
Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain
Personalis secured UKCA marking for its NeXT Personal Dx test, permitting clinical use of its Minimal Residual Disease detection technology across Great Britain.
The regulatory milestone allows global biopharma sponsors to standardize MRD detection across US and UK clinical trial sites, accelerating drug development timelines.
Link Medical Solutions Ltd. will serve as the business partner to commercialize the test and expand access for patients and clinicians in the region.
• 3mo ago AI analysis › Press Release
Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits
Personalis announced that its EDTA and cfDNA blood collection kits have obtained Class A CE-IVD marking under the EU’s In Vitro Diagnostic Regulation.
This regulatory clearance allows clinical trial sites in the European Union and Great Britain to use the kits for interventional studies, ensuring sample integrity for genomic analysis.
The milestone enables the global deployment of Personalis’ ultrasensitive NeXT Personal MRD detection platform for drug development programs, supporting large-scale clinical trials for biopharma partners.
• 4mo ago AI analysis › Press Release
Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026
Personalis presented clinical data at ASCO 2026 demonstrating the NeXT Personal MRD test achieved 100% sensitivity for colorectal cancer recurrence during surveillance and 82% sensitivity just four weeks post-surgery.
The company also highlighted ultrasensitive performance in lung cancer, detecting ctDNA at a median limit of 1.66 ppm, with patients showing sub-10 ppm levels facing a 3-fold increased risk of recurrence.
Additional studies across ovarian, endometrial, melanoma, and renal cell cancers reinforced the test's utility as a prognostic marker, with melanoma monitoring identifying recurrences a median of 212 days prior to imaging.
• 4mo ago AI analysis › Press Release
Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium
Personalis will present six clinical abstracts at the ASCO 2026 Annual Meeting, highlighting the broad utility of its NeXT Personal ctDNA test across six solid tumor types.
A key highlight is an oral podium presentation from the TRACERx consortium, demonstrating that NeXT Personal’s single-digit parts-per-million sensitivity identifies high-relapse-risk patients in early-stage non-small cell lung cancer.
Updated data from the VICTORI study in colorectal cancer showed 100% longitudinal sensitivity for recurrence and over 80% sensitivity as early as four weeks post-surgery, reinforcing the test’s clinical validity for minimal residual disease detection.
• 5mo ago AI analysis › Press Release
Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring
businesswire.com • 5mo ago Press Release
Personalis to Participate in Upcoming Investor Events
Personalis announced its management team will participate in two upcoming investor conferences.
The company will present at the Craig Hallum 23rd Annual Institutional Investor Conference on May 28, 2026, in Minneapolis.
It will also appear at the Jefferies 2026 Global Healthcare Conference on June 3, 2026, in New York.
• 5mo ago AI analysis › Press Release ● Major ⚠ 2
Personalis Reports First Quarter Results and Recent Highlights
Personalis reported Q1 clinical test volume surged 258% year-over-year to 7,815 tests, driven by the adoption of its NeXT Personal test and supported by new Medicare coverage for lung cancer surveillance.
Total revenue declined to $15.5 million from $20.6 million year-over-year, reflecting a strategic shift away from non-core revenue streams towards its MRD business.
The company ended the quarter with $233.2 million in cash and reaffirmed full-year 2026 guidance, targeting clinical revenue growth of roughly five-fold to $10.0-$11.0 million.
• 5mo ago AI analysis › Press Release
Personalis to Announce First Quarter 2026 Financial Results
Personalis will release its first quarter 2026 financial results on May 7, 2026.
A conference call and webcast are scheduled for 2:00 p.m. Pacific Time that day to discuss the results and business highlights.
• 6mo ago AI analysis › 
